Masateru Ohta
Cited by
Cited by
Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models
Y Yamashita-Kashima, S Iijima, K Yorozu, K Furugaki, M Kurasawa, ...
Clinical Cancer Research 17 (15), 5060-5070, 2011
Conformationally Restricted Analogs of 1α,25-Dihydroxyvitamin D3 and Its 20-Epimer:  Compounds for Study of the Three-Dimensional Structure of Vitamin D …
K Yamamoto, WY Sun, M Ohta, K Hamada, HF DeLuca, S Yamada
Journal of medicinal chemistry 39 (14), 2727-2737, 1996
Conformation− function relationship of vitamin D: conformational analysis predicts potential side-chain structure
S Yamada, K Yamamoto, H Masuno, M Ohta
Journal of medicinal chemistry 41 (9), 1467-1475, 1998
Three-dimensional structure-activity relationships and receptor mapping of N1-substituents of quinolone antibacterials
M Ohta, H Koga
Journal of medicinal chemistry 34 (1), 131-139, 1991
kGCN: a graph-based deep learning framework for chemical structures
R Kojima, S Ishida, M Ohta, H Iwata, T Honma, Y Okuno
Journal of Cheminformatics 12, 1-10, 2020
Imidazolidine derivatives
K Tachibana, H Sato, M Ohta, M Nakamura, T Shiraishi, I Imaoka, ...
US Patent 7,271,188, 2007
Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer
H Yoshino, H Sato, T Shiraishi, K Tachibana, T Emura, A Honma, ...
Bioorganic & medicinal chemistry 18 (23), 8150-8157, 2010
Design of potent K+ channel openers by pharmacophore model
H Koga, M Ohta, H Sato, T Ishizawa, N Hiroyuki
Bioorganic & Medicinal Chemistry Letters 3 (4), 625-631, 1993
Imidazolidine derivatives
K Tachibana, H Sato, M Ohta, M Nakamura, T Shiraishi, I Imaoka, ...
US Patent 7,803,826, 2010
Discovery of an orally-active nonsteroidal androgen receptor pure antagonist and the structure–activity relationships of its derivatives
K Tachibana, I Imaoka, T Shiraishi, H Yoshino, M Nakamura, M Ohta, ...
Chemical and Pharmaceutical Bulletin 56 (11), 1555-1561, 2008
Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2)
YH Han, Y Kato, M Haramura, M Ohta, H Matsuoka, Y Sugiyama
Pharmaceutical research 18, 579-586, 2001
On the side chain conformation of 1α, 25-dihydroxyvitamin D3 responsible for binding to the receptor
K Yamamoto, M Ohta, HF DeLuca, S Yamada
Bioorganic & Medicinal Chemistry Letters 5 (9), 979-984, 1995
High-precision atomic charge prediction for protein systems using fragment molecular orbital calculation and machine learning
K Kato, T Masuda, C Watanabe, N Miyagawa, H Mizouchi, S Nagase, ...
Journal of chemical information and modeling 60 (7), 3361-3368, 2020
Imidazolidine derivative and use thereof
K Tachibana, H Sato, M Ohta, M Nakamura, T Shiraishi, H Yoshino, ...
US Patent 8,470,829, 2013
Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination
T Shiraishi, S Kadono, M Haramura, H Kodama, Y Ono, H Iikura, T Esaki, ...
Bioorganic & medicinal chemistry letters 18 (16), 4533-4537, 2008
Structure–activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists
H Yoshino, H Sato, K Tachibana, T Shiraishi, M Nakamura, M Ohta, ...
Bioorganic & medicinal chemistry 18 (9), 3159-3168, 2010
Discovery of 7α-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure–activity relationships
K Tachibana, I Imaoka, H Yoshino, T Emura, H Kodama, Y Furuta, N Kato, ...
Bioorganic & Medicinal Chemistry 15 (1), 174-185, 2007
Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor
S Kadono, A Sakamoto, Y Kikuchi, M Oh-eda, N Yabuta, K Yoshihashi, ...
Biochemical and biophysical research communications 327 (2), 589-596, 2005
Structure-activity relationships of 6-substituted benzopyran-4-carbothioamide potassium channel openers
T Ishizawa, H Koga, M Ohta, H Sato, T Makino, K Kuromaru, N Taka, ...
Bioorganic & Medicinal Chemistry Letters 3 (8), 1659-1662, 1993
Lead optimization and avoidance of reactive metabolite leading to PCO371, a potent, selective, and orally available human parathyroid hormone receptor 1 (hPTHR1) agonist
Y Nishimura, T Esaki, Y Isshiki, Y Furuta, A Mizutani, T Kotake, T Emura, ...
Journal of Medicinal Chemistry 63 (10), 5089-5099, 2020
The system can't perform the operation now. Try again later.
Articles 1–20